Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 4/2015

01-08-2015 | ORIGINAL ARTICLE

Gender-Related Differences in Atherosclerosis

Authors: Pankaj Mathur, Bohuslav Ostadal, Francesco Romeo, Jawahar L. Mehta

Published in: Cardiovascular Drugs and Therapy | Issue 4/2015

Login to get access

Abstract

Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Considerable research has been done over the last several decades to understand the pathophysiology of atherosclerosis. It is widely believed that estrogen is responsible for the protection of women from CVD in the premenopausal age group. However, hormone replacement therapy has failed to decrease CVD events in clinical studies which points to the complexity of the relationship between vascular biology and estrogen hormones. Interestingly, preponderance of vascular and connective tissue disorders in women also points to an inherent role of hormones and tissue factors in maintenance of vascular endothelial function. The differential effect of GPER, lipoprotein A, TLRs, leucocyte-platelet aggregate markers in men and women also suggests inherent gender-related differences in the pathophysiology of atherosclerosis. A better understanding of the pathophysiology is likely to open ways to improve evidence-based treatment of CVD in women.
Literature
1.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399–410.CrossRefPubMed
2.
3.
4.
Steinberg D. Research related to underlying mechanisms in atherosclerosis. Circulation. 1979;60(7):1559–65.CrossRefPubMed
5.
Parthasarathy S, Quinn MT, Steinberg D. Is oxidized low density lipoprotein involved in the recruitment and retention of monocyte/macrophages in the artery wall during the initiation of atherosclerosis? Basic Life Sci. 1988;49:375–80.PubMed
6.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32.PubMed
7.
Duvall WL. Cardiovascular disease in women. Mt Sinay J Med. 2003;70:293–305.
8.
Fejfar Z. Prevention against ischaemic heart disease: a critical review. In: Oliver MF, editor. Modern trends in cardiology – 3. London: Butterworths; 1975. p. 465–95.
9.
Ostadal B, Ostadal P. Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. BJP. 2014;171:541–54.CrossRef
10.
Ostadal B, Netuka I, Maly J, Besik J, Ostadalova I. Gender differences in cardiac ischemic injury and protection-experimental aspects. Exp Biol Med (Maywood). 2009;234:1011–9.CrossRef
11.
Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS Registry study. J Am Coll Cardiol. 1995;25:1000–9.CrossRefPubMed
12.
Njolstad I, Arnesen E, Lund-Larsen PD. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark study. Circulation. 1996;93:450–6.CrossRefPubMed
13.
Stokes J, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation. 1987;75:V65–73.PubMed
14.
Kardys I, Vliegenthart R, Oudkerk M, Hofman A, Witteman JC. The female advantage in cardiovascular disease: do vascular beds contribute equally? Am J Epidemiol. 2007;166(4):403–12.CrossRefPubMed
15.
Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354–63.CrossRefPubMed
16.
Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 1998;97:2110–6.CrossRefPubMed
17.
Yahagi K, Davis HR, Arbustini E, Virmani R. Sex differences in coronary artery disease: pathological observations. Atherosclerosis. 2015;239(1):260–7.CrossRefPubMed
18.
Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation. 2010;122:2505–13.CrossRefPubMed
19.
Kolodgie FD, Burke AP, Farb A, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol. 2002;22:1642–8.CrossRefPubMed
20.
Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(24):2993–9.CrossRefPubMed
21.
Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women’s Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27(12):1408–15.CrossRefPubMed
22.
Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342(12):829–35.CrossRefPubMed
23.
Han SH, Bae JH, Holmes Jr DR, Lennon RJ, Eeckhout E, Barsness GW, et al. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J. 2008;29(11):1359–69.CrossRefPubMed
24.
Kern MJ, Bach RG, Mechem CJ, Caracciolo EA, Aguirre FV, Miller LW, et al. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation and coronary artery disease. J Am Coll Cardiol. 1996;28:1154–60.CrossRefPubMed
25.
Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124(13):1414–25.PubMedCentralCrossRefPubMed
26.
Iqbal SN, Feit F, Mancini GB, Wood D, Patel R, Pena-Sing I, et al. Characteristics of plaque disruption by intravascular ultrasound in women presenting with myocardial infarction without obstructive coronary artery disease. Am Heart J. 2014;167(5):715–22.CrossRefPubMed
27.
Sangiorgi G, Roversi S, Biondi Zoccai G, Modena MG, Servadei F, Ippoliti A, et al. Sex-related differences in carotid plaque features and inflammation. J Vasc Surg. 2013;57(2):338–44.CrossRefPubMed
28.
Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford). 2006;45 Suppl 3:iii3–4.
29.
Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takeshita A. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol. 2002;39(5):847–51.CrossRefPubMed
30.
Mohri M, Koyanagi M, Egashira K, Tagawa H, Ichiki T, Shimokawa H, et al. Angina pectoris caused by coronary microvascular spasm. Lancet. 1998;351(9110):1165–9.CrossRefPubMed
31.
Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141(5):735–41.CrossRefPubMed
32.
Harder DR, Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol. 1979;100:375–82.CrossRefPubMed
33.
Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, et al. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol. 1995;26(3):807–14.CrossRefPubMed
34.
Wilson TA, Nicolosi RJ, Lawton CW, Babiak J. Gender differences in response to a hypercholesterolemic diet in hamsters: effects on plasma lipoprotein cholesterol concentrations and early aortic atherosclerosis. Atherosclerosis. 1999;146(1):83–91.CrossRefPubMed
35.
Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Gender differences in atherosclerosis: possible role of nitric oxide. J Cardiovasc Pharmacol. 1995;26(5):792–802.CrossRefPubMed
36.
Huang A, Kaley G. Gender-specific regulation of cardiovascular function: estrogen as key player. Microcirculation. 2004;11(1):9–38.CrossRefPubMed
37.
Wagner AH, Schroeter MR, Hecker M. 17beta-e stradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J. 2001;15(12):2121–30.CrossRefPubMed
38.
Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X, et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104(3):288–91.PubMedCentralCrossRefPubMed
39.
Meyer MR, Fredette NC, Howard TA, Hu C, Ramesh C, Daniel C, et al. G protein-coupled estrogen receptor protects from atherosclerosis. Sci Rep. 2014;4:7564.PubMedCentralCrossRefPubMed
40.
Huang A, Koller A. Endothelin and prostaglandin H2 enhance arteriolar myogenic tone in hypertension. Hypertension. 1997;30:1210–5.CrossRefPubMed
41.
Huang A, Sun D, Koller A, Kaley G. Gender difference in myogenic tone of rat arterioles is due to estrogen-induced, enhanced release of NO. Am J Physiol. 1997;272:H1804–9.PubMed
42.
43.
Ng MK, Quinn CM, McCrohon JA, Nakhla S, Jessup W, Handelsman DJ, et al. Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol. 2003;42(7):1306–13.CrossRefPubMed
44.
McCrohon JA, Death AK, Nakhla N, et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation. 2000;101(3):224–6.CrossRefPubMed
45.
Ling S, Dai A, Williams MR, Myles K, et al. Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology. 2002;143(3):1119–25.CrossRefPubMed
46.
Hulley S, Grandy D, Bush T, Furberk C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–12.CrossRefPubMed
47.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg CH, Hutchison F, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized control trial. JAMA. 2002;288:321–33.CrossRefPubMed
48.
Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, et al. Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett. 2001;502(3):103–8.CrossRefPubMed
49.
Ghanam K, Lavagna C, Burgaud JL, Javellaud J, Ea-Kim L, Oudart N. Involvement of cyclooxygenase 2 in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit aorta. Biochem Biophys Res Commun. 2000;275:696–703.CrossRefPubMed
50.
Santos RL, Marin EB, Goncalves WL, Bissoli NS, Abreu GR, Moyses MR. Sex differences in the coronary vasodilatation induced by 17 β-oestradiol in the isolated perfused heart from spontaneously hypertensive rats. Acta Physiol (Oxf). 2010;200:203–10.CrossRef
51.
Murphy E, Steenbergen C. Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res. 2007;75:478–86.CrossRefPubMed
52.
Villablanca AC, Tenwolde A, Lee M, Huck M, Mumenthaler S, Rutledge JC. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009;2(3):289–99.PubMedCentralCrossRefPubMed
53.
Takada Y, Kato C, Kondo S, Korenaga R, Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun. 1997;240:737–41.CrossRefPubMed
54.
Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269–70.CrossRefPubMed
55.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605–19.CrossRefPubMed
56.
Piro M, Bona RD, Abbate A, Biasucci IM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol. 2010;55:1057–65.CrossRefPubMed
57.
Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30(2):234–8.CrossRefPubMed
58.
Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–9.CrossRefPubMed
59.
Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: a review. Int J Cardiol. 2010;142(1):8–14.CrossRefPubMed
60.
Jensen-Urstad K, Johansson J. Gender difference in age-related changes in vascular function. J Intern Med. 2001;250(1):29–36.CrossRefPubMed
61.
Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med. 2006;26(4):751–72.CrossRefPubMed
62.
Qasim AN, Martin SS, Mehta NN, Wolfe ML, Park J, Schwartz S, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol. 2011;150(1):17–21.PubMedCentralCrossRefPubMed
63.
Gremmel T, Kopp CW, Eichelberger B, Koppensteiner R, Panzer S. Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis. 2014;237(2):692–5.CrossRefPubMed
64.
Koupenova M, Mick E, Mikhalev E, Benjamin EJ, Tanriverdi K, Freedman JE. Sex differences in platelet toll-like receptors and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2015;35(4):1030–7.CrossRefPubMed
65.
Edfeldt K, Bennet AM, Eriksson P, Frostegård J, et al. Association of hypo-responsive toll- like receptor 4 variants with risk of myocardial infarction. Eur Heart J. 2004;25:1447–53.CrossRefPubMed
Metadata
Title
Gender-Related Differences in Atherosclerosis
Authors
Pankaj Mathur
Bohuslav Ostadal
Francesco Romeo
Jawahar L. Mehta
Publication date
01-08-2015
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 4/2015
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-015-6596-3

Other articles of this Issue 4/2015

Cardiovascular Drugs and Therapy 4/2015 Go to the issue

EDITORIAL

Women and Heart Disease; A Focus Issue

ORIGINAL ARTICLE

Vasotonic Angina as a Cause of Myocardial Ischemia in Women

ORIGINAL ARTICLE

The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women

ORIGINAL ARTICLE

The Role of 17β-Estradiol in Myocardial Hypertrophy in Females in the Presence and Absence of Hypertension

ORIGINAL ARTICLE

Gender Differences in Cardiovascular Drugs

ORIGINAL ARTICLE

Unique Aspects of Coronary Artery Disease in Indian Women

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits